๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Paroxysmal Nocturnal Hemoglobinuria
Clinical trial register · China

Paroxysmal Nocturnal Hemoglobinuria Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Tianjin 9 Beijing 6 Nanjing 4 Guangzhou 3 Wuhan 3
Narrow the registerReset
Recruitment status
Phase
Site location
Tianjin9 Beijing6 Nanjing4 Guangzhou3 Wuhan3
All 14 locations
Target enrolment
to

Paroxysmal Nocturnal Hemoglobinuria trials in China

17 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.
NCT07747090Paroxysmal Nocturnal Hemoglobinuria
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3
90
Tianjin
2026-12-10
Not yet open
A Long-term Efficacy and Safety of NTQ5082 Capsules
NCT07177872Paroxysmal Nocturnal Hemoglobinuria
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 3
78
Tianjin
2026-06
Recruiting
Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT07470762Paroxysmal Nocturnal Hemoglobinuria
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1/2
50
Hangzhou
2026-02-14
Not yet open
Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT07266155Paroxysmal Nocturnal Hemoglobinuria
DrugLP-005
Longbio Pharma
Phase 2
30
Nanjing
2025-12-05
Not yet open
A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients
NCT07177859Paroxysmal Nocturnal Hemoglobinuria
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 3
78
Tianjin
2025-11
By invitation
A Multicenter, Open-label Study Evaluating the Long-term Safety and Efficacy of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT07657052Paroxysmal Nocturnal Hemoglobinuria
S-INFINITY Pharmaceuticals Co., Ltd
Not applicable
26
Tianjin
2025-08-15
Recruiting
A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China
NCT06931691Paroxysmal Nocturnal Hemoglobinuria
Novartis Pharmaceuticals
Observational
80
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nantong, Nanchang, Changchun
2025-06-10
Active, closed
A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients
NCT06764303Paroxysmal Nocturnal Hemoglobinuria
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 2
24
Tianjin, Hangzhou
2025-01-23
Recruiting
Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT06745622Paroxysmal Nocturnal Hemoglobinuria
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
47
Nanjing
2025-01-03
Recruiting
Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
NCT06932471Paroxysmal Nocturnal Hemoglobinuria
Wuhan Createrna Science and Technology Co., Ltd
Phase 3
20
Beijing
2024-08-30
Active, closed
Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT06238544Paroxysmal Nocturnal Hemoglobinuria
Chengdu Suncadia Medicine Co., Ltd.
Phase 2
132
Beijing, Tianjin
2024-02-06
Active, closed
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104
NCT05476887Paroxysmal Nocturnal Hemoglobinuria
Kira Pharmacenticals (US), LLC.
Phase 2
35
Beijing, Nanjing, Tianjin, Zhengzhou
2022-11-25
Active, closed
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT04747613Paroxysmal Nocturnal Hemoglobinuria
Novartis Pharmaceuticals
Phase 3
208
Beijing, Tianjin
2021-07-27
Active, closed
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
NCT04434092Paroxysmal Nocturnal Hemoglobinuria
Hoffmann-La Roche
Phase 3
210
Beijing, Guangzhou, Hangzhou, Nanjing, Nantong, Shanghai, Wuhan
2020-10-08
Rows per page Showing 1–17 of 17
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/paroxysmal-nocturnal-hemoglobinuria

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 17 of those studies listing the condition Paroxysmal Nocturnal Hemoglobinuria.

How many Paroxysmal Nocturnal Hemoglobinuria trials are recruiting in China?

5 of the 17 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 4 have not yet opened recruitment, 7 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Paroxysmal Nocturnal Hemoglobinuria), 17 studies
PhaseStudiesRecruitingShare
Phase 39252.9%
Phase 25129.4%
Not applicable105.9%
Observational115.9%
Phase 1/2115.9%

Most active sponsors

Lead sponsors with the most studies (Paroxysmal Nocturnal Hemoglobinuria)
Lead sponsorStudiesRecruiting
Nanjing Chia-tai Tianqing Pharmaceutical30
Hoffmann-La Roche20
Novartis Pharmaceuticals21
Regeneron Pharmaceuticals21
Chengdu Suncadia Medicine Co., Ltd.10
Haisco Pharmaceutical Group Co., Ltd.11
Jiangsu Hansoh Pharmaceutical Co., Ltd.11
Kira Pharmacenticals (US), LLC.10
Longbio Pharma10
S-INFINITY Pharmaceuticals Co., Ltd10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.